- Home
- LITB vs OCX Comparison
LITB vs OCX Comparison
Compare LITB & OCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LITB
- OCX
- Stock Information
- Founded
- LITB 2007
- OCX 2009
- Country
- LITB Singapore
- OCX United States
- Employees
- LITB N/A
- OCX N/A
- Industry
- LITB Catalog/Specialty Distribution
- OCX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- LITB Consumer Discretionary
- OCX Health Care
- Exchange
- LITB Nasdaq
- OCX Nasdaq
- Market Cap
- LITB N/A
- OCX 80.1M
- IPO Year
- LITB N/A
- OCX N/A
- Fundamental
- Price
- LITB $1.03
- OCX $3.74
- Analyst Decision
- LITB
- OCX Buy
- Analyst Count
- LITB 0
- OCX 3
- Target Price
- LITB N/A
- OCX $4.42
- AVG Volume (30 Days)
- LITB 22.9K
- OCX 118.0K
- Earning Date
- LITB 03-24-2025
- OCX 04-11-2025
- Dividend Yield
- LITB N/A
- OCX N/A
- EPS Growth
- LITB N/A
- OCX N/A
- EPS
- LITB N/A
- OCX N/A
- Revenue
- LITB $333,093,000.00
- OCX $709,000.00
- Revenue This Year
- LITB N/A
- OCX N/A
- Revenue Next Year
- LITB N/A
- OCX $106.34
- P/E Ratio
- LITB N/A
- OCX N/A
- Revenue Growth
- LITB N/A
- OCX N/A
- 52 Week Low
- LITB $0.91
- OCX $1.92
- 52 Week High
- LITB $6.00
- OCX $4.75
- Technical
- Relative Strength Index (RSI)
- LITB 41.05
- OCX 67.14
- Support Level
- LITB $0.92
- OCX $3.25
- Resistance Level
- LITB $1.05
- OCX $4.75
- Average True Range (ATR)
- LITB 0.05
- OCX 0.49
- MACD
- LITB 0.01
- OCX 0.07
- Stochastic Oscillator
- LITB 61.54
- OCX 58.42
About OCX Oncocyte Corporation
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.